Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.

MLA

Bellmunt, J., et al. “Borealis-1: A Randomized, First-Line, Placebo-Controlled, Phase II Study Evaluating Apatorsen and Chemotherapy for Patients with Advanced Urothelial Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 28, no. 10, Oct. 2017, pp. 2481–88. EBSCOhost, https://doi.org/10.1093/annonc/mdx400.

APA

Bellmunt, J., Eigl, B. J., Senkus, E., Loriot, Y., Twardowski, P., Castellano, D., Blais, N., Sridhar, S. S., Sternberg, C. N., Retz, M., Pal, S., Blumenstein, B., Jacobs, C., Stewart, P. S., & Petrylak, D. P. (2017). Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 28(10), 2481–2488. https://doi.org/10.1093/annonc/mdx400

Chicago

Bellmunt, J, B J Eigl, E Senkus, Y Loriot, P Twardowski, D Castellano, N Blais, et al. 2017. “Borealis-1: A Randomized, First-Line, Placebo-Controlled, Phase II Study Evaluating Apatorsen and Chemotherapy for Patients with Advanced Urothelial Cancer.” Annals of Oncology : Official Journal of the European Society for Medical Oncology 28 (10): 2481–88. doi:10.1093/annonc/mdx400.